The Phase I/II trial NCT02688686 evaluates the safety and efficiency of a DC-based vaccine encoding suppressor of cytokine signaling 1 (SOCS1), MUC-1, and survivin, in combination with cytokine-induced killer (CIK) cells, in patients with advanced NSCLC with bone metastases who received standardized treatment (n = 30). This evidence concerns the gene MUC1 and non-small cell lung carcinoma.